ライフサイエンスコーパス: delayed-type hypersensitivity

1 expression of the IL-2 receptor and promoted delayed type hypersensitivity.

2 gal and inhibited the ear-swelling assay for delayed type hypersensitivity.

3 ogical exams and demonstration of leishmanin delayed-type hypersensitivity.

4 nodes and to the inflamed paw in a model of delayed-type hypersensitivity.

5 cytokines associated with the development of delayed-type hypersensitivity.

6 r apoptotic activity using a murine model of delayed-type hypersensitivity.

7 rized by impairment of Th1 responses such as delayed-type hypersensitivity.

8 on (IFN-gamma), nitric oxide production, and delayed-type hypersensitivity.

9 ion of Th1 splenocytes and increased in vivo delayed-type hypersensitivity.

10 ion of macrophage influx in a mouse model of delayed-type hypersensitivity.

11 hocytes, as well as an inability to manifest delayed-type hypersensitivity.

12 te-induced peritonitis and oxazolone-induced delayed-type hypersensitivity.

13 immediate-type hypersensitivity; and reduced delayed-type hypersensitivity.

14 immediate-type hypersensitivity and enhanced delayed-type hypersensitivity.

15 es immunologic memory and the elicitation of delayed-type hypersensitivity.

16 d induction of sepsis-induced suppression of delayed-type hypersensitivity.

17 liferation of human TEM cells and suppresses delayed type hypersensitivity, a TEM cell-mediated react

18 ction of antigen inhibits the development of delayed-type hypersensitivity, a phenomenon known as ant

19 mice exhibited T cell priming by peptide and delayed-type hypersensitivity, although these responses

20 tein 60 was the only antigen shown to induce delayed-type hypersensitivity among other antigens teste

21 eactive T cells by ELISPOT and by trans-vivo delayed-type hypersensitivity analysis in a surrogate mu

22 tivity, and cytokine production in vitro and delayed type hypersensitivity and inflammatory bowel dis

23 Immunologic response was monitored by delayed-type hypersensitivity and [(3)H]thymidine prolif

24 HHE) associated with salutary or detrimental delayed-type hypersensitivity and AIDS phenotypes, respe

25 Myosin-specific delayed-type hypersensitivity and antibody production we

26 or in vivo inhibition, causing enhanced skin delayed-type hypersensitivity and antigen (Ag)-induced a

27 s several type 1 immune responses, including delayed-type hypersensitivity and autoimmunity in which

28 T cell responses and reduced inflammation in delayed-type hypersensitivity and clinical disease in EA

29 lammation and autoimmunity, murine models of delayed-type hypersensitivity and collagen-induced arthr

30 A in the a.c. displayed reduced OVA-specific delayed-type hypersensitivity and CTL responses, compare

31 Skin delayed-type hypersensitivity and experimental autoimmun

32 ific mAb inhibited T cell-mediated models of delayed-type hypersensitivity and experimental autoimmun

33 Furthermore, allospecific delayed-type hypersensitivity and gene expression of int

34 Delayed-type hypersensitivity and humoral immune respons

35 f AnxA1 also increased OVA-induced cutaneous delayed-type hypersensitivity and IFN-gamma and IL-17 re

36 lin epitope-specific Th1 effector functions (delayed-type hypersensitivity and IFN-gamma production)

37 ducing T lymphocyte-mediated inflammation in delayed-type hypersensitivity and in experimental autoim

38 Contact sensitivity (CS) is related to delayed-type hypersensitivity and is a well-characterize

39 reated mice, as indicated by reduced in vivo delayed-type hypersensitivity and reduced levels of sple

40 icking to draining lymph nodes, induction of delayed-type hypersensitivity and rejection of corneal t

41 Further, when delayed-type hypersensitivity and splenic T cell prolife

42 age-related T cell dysfunction, Ag-specific delayed-type hypersensitivity and T cell proliferation w

43 n control IgG exhibited impaired Ag-specific delayed-type hypersensitivity and T cell proliferation,

44 e candidates due to their capacity to elicit delayed-type hypersensitivity and Th type 1-like cytokin

45 that excessive activity of T cells mediates delayed-type hypersensitivity and that cellular cytolysi

46 4 and CD8 effector responses in vivo, namely delayed-type hypersensitivity and tumor immunity.

47 nd gastric epithelial metaplasia), cellular (delayed-type hypersensitivity) and humoral immune respon

48 reactions triggered by immune (immediate and delayed-type hypersensitivity) and non-immune (intoleran

49 me-linked immunosorbent assay, Western blot, delayed type hypersensitivity, and enzyme-linked immunos

50 , MAS, mean and cumulative arthritis scores, delayed-type hypersensitivity, and antibody responses to

51 , suppress primarily Th1 responses including delayed-type hypersensitivity, and transfer suppression

52 Chlamydial delayed-type hypersensitivity antigens were analyzed by

53 tic capacity of uPA in the CIA model and the delayed-type hypersensitivity arthritis model.

54 reduced arthritis progression in the CIA and delayed-type hypersensitivity arthritis models.

55 onor-specific regulation (DSR) by trans-vivo delayed type hypersensitivity assay at the time of enrol

56 rs before transplant and used the trans-vivo-delayed type hypersensitivity assay to measure immune re

57 The transvivo delayed type hypersensitivity assay was used to analyze

58 transplants as responders in the trans vivo-delayed type hypersensitivity assay, we found that dendr

59 Techniques, such as the trans vivo delayed-type hypersensitivity assay, ELISPOT and antigen

60 al blood of 45 patients using the trans-vivo delayed-type hypersensitivity assay.

61 MSCs was studied in vivo in a mouse model of delayed-type hypersensitivity assay.

62 from C57BL/6 CD4 KO mice were assessed using delayed-type hypersensitivity assays and Annexin V apopt

63 Delayed-type hypersensitivity assays demonstrated that i

64 Mixed-lymphocyte reactions and delayed-type hypersensitivity assays were performed to e

65 nies many type 1 immune responses, including delayed-type hypersensitivity, autoimmunity, and graft r

66 Delayed-type hypersensitivity, CD4 and CD8 counts, anti-

67 Immune responses were evaluated by delayed-type hypersensitivity, CD4+ T-cell proliferation

68 In a more generalized model of inflammation, delayed-type hypersensitivity, CP-481,715 significantly

69 21 significantly enhanced the Th1-associated delayed-type hypersensitivity cutaneous responses.

70 HER2-specific delayed-type hypersensitivity developed in most patients

71 ection against disseminated candidiasis, but delayed-type hypersensitivity did.

72 Suppression of delayed type hypersensitivity (DTH) and in vivo lymphopr

73 tion correlates with a strong induction of a delayed type hypersensitivity (DTH) response following e

74 Maternal exposure to dLAN dampened delayed type hypersensitivity (DTH) responses in male of

75 IMP-1 and TIMP-2 had differential effects on delayed type hypersensitivity (DTH) responses to donor a

76 In this study, we show that cutaneous delayed type hypersensitivity (DTH) responses to recall

77 bined immunodeficiency mice to measure human delayed type hypersensitivity (DTH) responses.

78 ed immunoglobulin G (IgG) autoantibodies and delayed type hypersensitivity (DTH) to cardiac myosin.

79 antibodies and histopathologic, RT-PCR, and delayed-type hypersensitivity (DTH) analyses were used t

80 ompanied by vigorous cardiac myosin-specific delayed-type hypersensitivity (DTH) and antibody product

81 these mice developed cardiac myosin-specific delayed-type hypersensitivity (DTH) and autoantibodies i

82 st skin-infiltrating lymphocytes in allergic delayed-type hypersensitivity (DTH) and bacterial chancr

83 acy of JAK-3 inhibitors was determined using delayed-type hypersensitivity (DTH) and collagen-induced

84 e absence of injury, aged mice had depressed delayed-type hypersensitivity (DTH) and splenocyte proli

85 In 14 of 14 patients, delayed-type hypersensitivity (DTH) and/or CD4 prolifera

86 Delayed-type hypersensitivity (DTH) assays demonstrate t

87 We explored the feasibility of measuring delayed-type hypersensitivity (DTH) following intraderma

88 g spleen Th1 cells, specific serum IgG2a, or delayed-type hypersensitivity (DTH) footpad reactions we

89 , interleukin-2-induced pulmonary edema, and delayed-type hypersensitivity (DTH) in mice.

90 s mediate the suppression of donor-specific, delayed-type hypersensitivity (DTH) in tolerant organ tr

91 The effects of age, sex, and prevaccination delayed-type hypersensitivity (DTH) on the time course o

92 positive (responsive) or negative (anergic), delayed-type hypersensitivity (DTH) reaction to intrader

93 Safety, toxicity, delayed-type hypersensitivity (DTH) reaction, and induct

94 ntigen is injected, resulting in a classical delayed-type hypersensitivity (DTH) reaction.

95 All lesions were caused by allergic delayed-type hypersensitivity (DTH) reactions and not by

96 Delayed-type hypersensitivity (DTH) reactions elicited b

97 tory lymphokine essential for elicitation of delayed-type hypersensitivity (DTH) reactions in vivo.

98 the selectins play a role and predominate in delayed-type hypersensitivity (DTH) reactions of the ski

99 Systemic exposure to LTA or CPAF inhibited delayed-type hypersensitivity (DTH) reactions to the che

100 l inflammatory diseases including psoriasis, delayed-type hypersensitivity (DTH) reactions, and rheum

101 eumatoid arthritis, psoriasis, and cutaneous delayed-type hypersensitivity (DTH) reactions.

102 iphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions.

103 e and central memory subsets and inhibit the delayed-type hypersensitivity (DTH) response caused by s

104 o sand fly saliva in rodents induces a T(H)1 delayed-type hypersensitivity (DTH) response conferring

105 val, adverse events (AEs), and the effect of delayed-type hypersensitivity (DTH) response on clinical

106 There was a significant delayed-type hypersensitivity (DTH) response to adjuvant

107 /6 mice with indoles (I3C or DIM) attenuated delayed-type hypersensitivity (DTH) response to methylat

108 plex virus type 1 (HSV-1) develop a vigorous delayed-type hypersensitivity (DTH) response upon intrad

109 Delayed-type hypersensitivity (DTH) response was detecte

110 ized severe C. pneumoniae disease as being a delayed-type hypersensitivity (DTH) response with increa

111 antigen-specific proliferation in vitro, the delayed-type hypersensitivity (DTH) response, and serum

112 uppression in septic patients is an impaired delayed-type hypersensitivity (DTH) response, manifested

113 cterium bovis-specific antigens to stimulate delayed-type hypersensitivity (DTH) responses in cattle

114 n PPD were tested for the capacity to induce delayed-type hypersensitivity (DTH) responses in H37Rv-i

115 mmune cell infiltration at vaccine sites and delayed-type hypersensitivity (DTH) responses to autolog

116 Previously, we reported postvaccination delayed-type hypersensitivity (DTH) responses to autolog

117 The delayed-type hypersensitivity (DTH) responses to intrade

118 disease had high IgG antibody titers and no delayed-type hypersensitivity (DTH) responses to Leishma

119 mmunity, we hypothesized that decreased skin delayed-type hypersensitivity (DTH) responses to recall

120 to induce efferent T reg cells and suppress delayed-type hypersensitivity (DTH) responses.

121 ng, in vitro peptide recognition assays, and delayed-type hypersensitivity (DTH) responses.

122 not Th2 clones, induced alloantigen-specific delayed-type hypersensitivity (DTH) responses.

123 response to graft alloantigens at a distant delayed-type hypersensitivity (DTH) site would force the

124 ns ESAT-6, CFP-10, MPB70, and MPB83 elicited delayed-type hypersensitivity (DTH) skin test responses

125 otein antigen (TA90) expressed by PV, and by delayed-type hypersensitivity (DTH) skin testing with PV

126 Delayed-type hypersensitivity (DTH) testing in vivo and

127 the Ag-specific down-regulation of systemic delayed-type hypersensitivity (DTH) that is induced when

128 egimen suppressed the strong myosin-specific delayed-type hypersensitivity (DTH) that normally develo

129 Patients were tested for delayed-type hypersensitivity (DTH) to autologous melano

130 polygyrus infection reduced the magnitude of delayed-type hypersensitivity (DTH) to PPD in the skin.

131 The challenged WT mice developed delayed-type hypersensitivity (DTH) to SEA; high levels

132 Allospecific delayed-type hypersensitivity (DTH) was evaluated after

133 rfered with cell-mediated immunity as myosin delayed-type hypersensitivity (DTH) was reduced, while a

134 Hapten-evoked cutaneous delayed-type hypersensitivity (DTH) was significantly en

135 ssential mediators of autoimmune disease and delayed-type hypersensitivity (DTH), a convenient model

136 t survival, graft infiltration, allospecific delayed-type hypersensitivity (DTH), and cytokine expres

137 uble RAGE treatment is effective in reducing delayed-type hypersensitivity (DTH), even in RAGE(-/-) m

138 Delayed swelling reactions, i.e., delayed-type hypersensitivity (DTH), in response to an i

139 responsiveness by the ear-swelling test for delayed-type hypersensitivity (DTH), in vitro proliferat

140 Delayed-type hypersensitivity (DTH), suggesting T-cell r

141 This process resulted in a delayed-type hypersensitivity (DTH)-like EAE lesion.

142 were confirmed in vivo in a murine model of delayed-type hypersensitivity (DTH).

143 mals were unresponsive to PLP as measured by delayed-type hypersensitivity (DTH).

144 n and prevent the generation of allospecific delayed-type hypersensitivity (DTH).

145 ked the effects of UV in vivo and suppressed delayed-type hypersensitivity (DTH).

146 rized by donor-antigen-linked suppression of delayed-type hypersensitivity (DTH).

147 of immunity by B. dendrobatidis, a modified delayed-type-hypersensitivity (DTH) protocol was develop

148 T-cell (proliferation and delayed type hypersensitivity [DTH]) and B-cell (antibod

149 ic VL, (ii) asymptomatic infection (positive delayed-type hypersensitivity [DTH+]), or (iii) no evide

150 e differed from wild-type in the severity of delayed-type hypersensitivity (edema, T-cell and neutrop

151 respect to disease induction, enhancement of delayed-type hypersensitivity, enhancement of lymphocyte

152 clude mixed lymphocyte reactions, trans-vivo delayed-type hypersensitivity, enzyme-linked immunospot

153 immunopathology was found to be operative in delayed-type hypersensitivity footpad-swelling reaction

154 Several models, including delayed type hypersensitivity in immune mice, and sponta

155 rotein showed potent in vivo efficacy in the delayed type hypersensitivity in rats.

156 these cells to present Ag for elicitation of delayed-type hypersensitivity in previously immunized mi

157 of Th2 enhancement, as indicated by reduced delayed-type hypersensitivity in the context of enhanced

158 to inhibit T-cell proliferation and control delayed-type hypersensitivity in vivo.

159 es of T cell function--ranging from positive delayed-type hypersensitivity, in asymptomatic infected

160 press the keyhole limpet hemocyanin-specific delayed-type hypersensitivity inflammatory response.

161 autoreactive anti-MPO CD4(+) cells to induce delayed type hypersensitivity-like necrotizing glomerula

162 ain aspects of immune function, particularly delayed-type hypersensitivity, may be improved in HD pat

163 sessment of Th1 function using the cutaneous delayed-type hypersensitivity model confirmed that p53(-

164 stopathological analysis of tissues from the delayed-type hypersensitivity model demonstrates that in

165 ed CD4(+) T-cell immune response in a murine delayed-type hypersensitivity model in vivo.

166 In a delayed-type hypersensitivity model, both T cell infiltr

167 able to reduce inflammation in a murine paw delayed-type hypersensitivity model, suppress the onset

168 ted anti-inflammatory properties in a murine delayed-type hypersensitivity model.

169 a T cells do not cause direct suppression of delayed-type hypersensitivity nor do they act as tolerog

170 hat disease is mediated by antigen-dependent delayed-type hypersensitivity or autoimmunity.

171 ration or cytokine production, or in vivo by delayed-type hypersensitivity or bystander suppression a

172 velopment of specific antibody (P = .025) or delayed-type hypersensitivity (P = .03) responses to EGF

173 Sixteen subjects (out of 315 with CS delayed-type hypersensitivity) presented with allergic m

174 f systemically activated T cells home to the delayed type hypersensitivity reaction induced by the ov

175 tenuated in subjects who are able to mount a delayed type hypersensitivity reaction to M. tuberculosi

176 s on ITK, which reduces an oxazolone-induced delayed type hypersensitivity reaction.

177 nodes (LNs) of mice with cOVA-induced airway delayed-type hypersensitivity reaction (DTHR) but not in

178 king RON exhibit increased inflammation in a delayed-type hypersensitivity reaction and increased sus

179 In a delayed-type hypersensitivity reaction in vivo, compound

180 A delayed-type hypersensitivity reaction test was administ

181 el of experimentally induced peritonitis and delayed-type hypersensitivity reaction.

182 easured from inhibition of ear swelling in a delayed-type hypersensitivity reaction.

183 quisition of the capacity to mount cutaneous delayed type hypersensitivity reactions that disappeared

184 K14-mOVA Tg mice failed to mount T cell and delayed type hypersensitivity reactions to OVA, suggesti

185 However, severe delayed-type hypersensitivity reactions (DHR) induced by

186 d with E. chaffeensis, the animals developed delayed-type hypersensitivity reactions at cutaneous sit

187 naling of human T cells in vitro and reduces delayed-type hypersensitivity reactions in rats in vivo.

188 terolemia is frequent in these patients, and delayed-type hypersensitivity reactions in the arterial

189 TIGIT-Fc inhibited delayed-type hypersensitivity reactions in wild-type but

190 ve indicated that UVB-mediated inhibition of delayed-type hypersensitivity reactions is mediated, in

191 Posttreatment induction of delayed-type hypersensitivity reactions to autologous le

192 Patients have developed delayed-type hypersensitivity reactions to E75 postvacci

193 Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, d

194 Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, d

195 2) in the control of cutaneous inflammation, delayed-type hypersensitivity reactions were elicited in

196 e responses against intracellular pathogens, delayed-type hypersensitivity reactions, and induction o

197 d exhibited normal T cell priming and normal delayed-type hypersensitivity reactions.

198 ce compared with wild-type littermates after delayed-type hypersensitivity reactions.

199 han of PPD were needed to induce substantial delayed-type hypersensitivity reactions.

200 ine known to be essential for development of delayed-type hypersensitivity reactions.

201 global immunity as reflected by an enhanced delayed type hypersensitivity response and a 1.7-fold im

202 rechallenge prevented the development of the delayed type hypersensitivity response in vivo.

203 cellular immune responses were determined by delayed-type hypersensitivity response and by a prolifer

204 showed that IL-27 regulated the severity of delayed-type hypersensitivity response and EAE through i

205 icance of the role of IL-27 was addressed in delayed-type hypersensitivity response and experimental

206 ignificantly stronger CD4(+) T-cell-mediated delayed-type hypersensitivity response and resulted in s

207 ry effect of alpha(1)beta(1) blockade on the delayed-type hypersensitivity response could be bypassed

208 owever, IL-10-deficient mice had an enhanced delayed-type hypersensitivity response during the chroni

209 ed allografts did not elicit an alloreactive delayed-type hypersensitivity response in graft recipien

210 VIP inhibited elicitation of a delayed-type hypersensitivity response in previously imm

211 fluence of photoperiod and acute stress on a delayed-type hypersensitivity response in the skin.

212 In a pattern-I-type delayed-type hypersensitivity response model, a similar

213 Inhibition of the delayed-type hypersensitivity response required that the

214 In contrast, the delayed-type hypersensitivity response to alloantigen wa

215 IL-10 transgenic mice demonstrated a smaller delayed-type hypersensitivity response to allogeneic cel

216 lymph nodes and allografts, 2) a suppressed delayed-type hypersensitivity response to B6D2F1 Ags, an

217 rative responses and a significantly reduced delayed-type hypersensitivity response to challenge anti

218 trates demonstrated a much weaker peripheral delayed-type hypersensitivity response to donor alloanti

219 et KO cells, gastritis was associated with a delayed-type hypersensitivity response to H. pylori anti

220 Lastly, P763.74, but not PGH786, induced a delayed-type hypersensitivity response to HMW-MAA-bearin

221 spleen T cells in vitro and inhibition of a delayed-type hypersensitivity response to oxazolone in v

222 on-induced immunosuppression, resulting in a delayed-type hypersensitivity response to photo-induced

223 -MEM mice responded with an enhanced footpad delayed-type hypersensitivity response, and more IFN-gam

224 lin E and inhibition of the anticryptococcal delayed-type hypersensitivity response, indicating a shi

225 nths), and recurrence correlated with a weak delayed-type hypersensitivity response.

226 condary infection, and exhibited an impaired delayed-type hypersensitivity response.

227 onsequently, these cells failed to sustain a delayed-type hypersensitivity response.

228 t not CpG 1826/IFA as an adjuvant elicited a delayed-type hypersensitivity response.

229 allogeneic tumor cells or the suppression of delayed type hypersensitivity responses against soluble

230 In addition, delayed type hypersensitivity responses are strongly imp

231 g/day) demonstrated significant decreases in delayed type hypersensitivity responses to tetanus, inte

232 rdiac myosin (autoimmunity) but did decrease delayed-type hypersensitivity responses against both ant

233 , characterized by Ag-specific inhibition of delayed-type hypersensitivity responses and a reduction

234 n the periphery, which resulted in increased delayed-type hypersensitivity responses and autoimmune d

235 ACAID is characterized by decreases in delayed-type hypersensitivity responses and complement-f

236 These results indicate that delayed-type hypersensitivity responses are heterogeneou

237 Our data demonstrate that decorin modulates delayed-type hypersensitivity responses by augmenting th

238 induced Ag-specific T cell proliferation and delayed-type hypersensitivity responses in FcgammaRIIB-e

239 orphisms and haplotype pairs that influenced delayed-type hypersensitivity responses in healthy perso

240 reduced IFN-gamma production, and inhibited delayed-type hypersensitivity responses in immune mice c

241 ls, which failed to undergo proliferative or delayed-type hypersensitivity responses in recipients.

242 ma tumor cells, and tumor-loaded DC1s induce delayed-type hypersensitivity responses in vivo.

243 zation, because Jak3-/- chimeric mice showed delayed-type hypersensitivity responses indistinguishabl

244 They also display DBA/2-reactive delayed-type hypersensitivity responses that are activel

245 administration of MSCs significantly reduced delayed-type hypersensitivity responses to allogeneic an

246 Delayed-type hypersensitivity responses to C57BL/6 alloa

247 ermined by the level of serum antibodies and delayed-type hypersensitivity responses to HMW-MAA-beari

248 yeloperoxidase CD4+ T cells, enhanced dermal delayed-type hypersensitivity responses to myeloperoxida

249 Liver but not spleen pDCs suppress delayed-type hypersensitivity responses to OVA, an effec

250 Furthermore, 139-iTregs inhibit delayed-type hypersensitivity responses to PLP139-151, b

251 n 42 patients with leprosy were compared for delayed-type hypersensitivity responses to purified prot

252 in vitro proliferative responses and in vivo delayed-type hypersensitivity responses to the allogenei

253 ount but was associated with higher rates of delayed-type hypersensitivity responses to TT (25% of su

254 of murine CD8(+) dendritic cells to suppress delayed-type hypersensitivity responses to tumor-associa

255 Baseline delayed-type hypersensitivity responses were enhanced du

256 Further, high T-cell-proliferative- and delayed-type hypersensitivity responses were seen in Pey

257 41 vaccination decreased corneal opacity and delayed-type hypersensitivity responses while elevating

258 combinant murine IL-10 were able to suppress delayed-type hypersensitivity responses within injected

259 We used cutaneous delayed-type hypersensitivity responses, a powerful in v

260 Cs including enhanced T-cell reconstitution, delayed-type hypersensitivity responses, and class-switc

261 nterferon gamma-producing T cells, increased delayed-type hypersensitivity responses, and higher seru

262 es: rash, high fever, viremia, depression of delayed-type hypersensitivity responses, lowered leukocy

263 not age, was associated with impairments in delayed-type hypersensitivity responses, lymphoprolifera

264 ed bystander suppression of tetanus-specific delayed-type hypersensitivity responses, which was rever

265 rvival demonstrated prominent donor-reactive delayed-type hypersensitivity responses, which were incr

266 G(35-55) in vitro and demonstrated decreased delayed-type hypersensitivity responses.

267 They had significant leukopenia and reduced delayed-type hypersensitivity responses.

268 sitivity and enhancement of antigen-specific delayed-type hypersensitivity responses.

269 corin modulates leukocyte recruitment during delayed-type hypersensitivity responses.

270 cross-regulation of Th1 cells or exaggerated delayed-type hypersensitivity responses.

271 tor and memory T cells inhibited Ag-specific delayed-type hypersensitivity responses; similar decreas

272 inished memory T-cell populations, decreased delayed-type-hypersensitivity responses and decreased in

273 beta1AR(-/-) mice had improved cellular (delayed-type hypersensitivity) responses while beta2AR(-

274 Analysis by transvivo delayed type hypersensitivity showed that the reactivity

275 sponses to rabies and pneumococcus vaccines, delayed-type hypersensitivity skin reactions, and mucosa

276 ed antigen-specific T-cell proliferation and delayed-type hypersensitivity skin response.

277 Delayed-type hypersensitivity skin test responses were m

278 ral load, baseline CD4(+) T cell counts, and delayed-type hypersensitivity skin test responses, an in

279 assessed by in vitro proliferation assay and delayed-type hypersensitivity skin testing.

280 Delayed-type hypersensitivity skin tests showed that som

281 Using Ag-specific delayed-type hypersensitivity, T cell proliferation, and

282 induced by IFN-gamma, TNF, TLR agonists, and delayed-type hypersensitivity than CCR4(-) cells.

283 n a mucosal tolerization schedule suppressed delayed type hypersensitivity to E-selectin confirming t

284 hermore, ATPgammaS enhanced the induction of delayed-type hypersensitivity to a model tumor vaccine i

285 itivity responses are heterogeneous and that delayed-type hypersensitivity to alloantigen is not a su

286 in the hosts and inhibited the expression of delayed-type hypersensitivity to donor alloantigens.

287 BALB/c mice with pre-established delayed-type hypersensitivity to hen OVA were immunized

288 of healthy subjects have tested positive for delayed-type hypersensitivity to soluble leishmania anti

289 ed immunologic memory and the elicitation of delayed-type hypersensitivity to the common opportunisti

290 filtrates responded strongly to donor Ags in delayed-type hypersensitivity trans-vivo assays.

291 atic acid phosphatase (PAP) and a trans-vivo delayed-type hypersensitivity (tvDTH) assay, we found th

292 vels of inflammation were seen in a model of delayed-type hypersensitivity using 2,4-dinitrofluoroben

293 Additionally, allospecific delayed-type hypersensitivity was compared among the gro

294 Delayed-type hypersensitivity was enhanced in women with

295 In the mouse model of delayed type hypersensitivity, we have shown an essentia

296 proliferation of T(EM) cells and suppresses delayed type hypersensitivity when administered at 10 or

297 nted a hallmark of sepsis (i.e., the loss of delayed-type hypersensitivity), which is an IFN-gamma- a

298 lls and prevented these mice from developing delayed-type hypersensitivity, which is critically depen

299 nate immune activation to medication-induced delayed-type hypersensitivity, which may stimulate new c

300 The correlations of increased delayed-type hypersensitivity with -2459G/G-containing C